Cost-effectiveness analysis compares biosimilar denosumab with bisphosphonates, indicating better patient access to treatment.
Biosimilar denosumab was estimated to be cost-effective compared with alendronate, risedronate, ibandronate, and zoledronic acid at a WTP threshold of $150,000/QALY gained and compared with risedronate at a threshold of $100,000/QALY gained. As a lower-cost alternative to reference denosumab, biosimilar denosumab may enhance patient access to effective PMO treatment in the USA.
No takes yet. Share an insight, caveat, or question.
Flanigan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: